Crohn's Disease Market

Crohn's Disease Market Size is anticipated to grow at a CAGR of 7.6% for the study period 2018–2030 | DelveInsight

Crohn’s disease is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus. Additionally, ulcerative colitis, an IBD that causes long-lasting inflammation and ulcers (sores) in your digestive tract, is limited to the colon, also called the large intestine. CROHN’S DISEASE is characterized by skip intestinal lesions (that is, areas of inflammation interposed between normal-appearing mucosa) anywhere in the GI tract. It involves chronic, relapsing transmural inflammation that can lead to Chronic abdominal pain, diarrhea, obstruction and/or perianal lesions.

DelveInsight’s ‘Crohn’s Disease Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the Crohn’s Disease, historical and forecasted epidemiology as well as the Crohn’s Disease market trends in the United States.

Some facts of Crohn’s Disease Market are:

· In the year 2020, the total prevalent case of Crohn’s Disease was 825,165 cases in the United States which are expected to grow during the forecast period, i.e., 2021–2030.

· The disease epidemiology covered in the report provides historical as well as forecasted Crohn’s Disease epidemiology [segmented as Total Prevalent Cases of Crohn’s Disease, Total Diagnosed Cases of Crohn’s Disease, Age-specific cases of Crohn’s Disease, Severity-specific Cases of Crohn’s Disease, and Treated cases of Crohn’s Disease] in the United States from 2018 to 2030.

· The US FDA-approved biologics for the treatment of Crohn’s Disease include infliximab, adalimumab, certolizumab, vedolizumab, natalizumab, ustekinumab.

· Growth of the Crohn’s Disease market is expected to be mainly driven by the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/advanced therapies, advances in research and development, new biomarkers for diagnosis of Crohn’s Disease, and increasing prevalence of Crohn’s Disease.

View Report: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Request for Sample Report: https://www.delveinsight.com/sample-request/crohns-disease-cd-market

Crohn’s Disease Report Scope

• The report covers the descriptive overview of Crohn’s Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Crohn’s Disease epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Crohn’s Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of Crohn’s Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Crohn’s Disease market

Crohn’s Disease Therapies covered:

· Jyselica/Filgotinib (Gilead Sciences/Galapagos NV)

· Rinvoq/Upadacitinib (AbbVie)

· Etrolizumab/RG 7413 (Hoffmann-La Roche/Genentech)

· Ozanimod/Zeposia (Celgene)

· Skyrizi/Risankizumab (AbbVie/Boehringer Ingelheim)

· Brazikumab/MEDI-2070 (Astrazeneca)

· Alofisel/Darvadstrocel (Takeda/TiGenix)

· Mirikizumab/LY-3074828 (Eli Lilly and Company)

· RHB-104 (RedHill Biopharma)

· Etrasimod/APD334 (Arena Pharmaceuticals)

· Tremfya/Guselkumab (Janssen)

· Deucravacitinib/BMS-986165 (Bristol-Myers Squibb)

· Tesnatilimab/JNJ-64304500 (Janssen)

· Sibofimloc/EB8018 (Takeda/Enterome)

· BT-11 (Landos Biopharma)

· UTTR1147A/RG 7880 (Genentech)

· TD-1473/JNJ 8398 (Theravance Biopharma/Janssen)

· JNJ-67864238/PTG 200 (Protagonist Therapeutics/Janssen)

· SHR0302 (Reistone Biopharma)

· Ryoncil/Remestemcel-L (Mesoblast)

· Ritlecitinib/Brepocitinib (Pfizer)

View Report: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Request for Sample Report: https://www.delveinsight.com/sample-request/crohns-disease-cd-market

Table of content

1. Key Insights

2. Executive Summary of Crohn’s Disease

3. Competitive Intelligence Analysis for Crohn’s Disease

4. Crohn’s Disease: Market Overview at a Glance

5. Crohn’s Disease: Disease Background and Overview

6. Patient Journey

7. Crohn’s Disease Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Crohn’s Disease Treatment

11. Marketed Products

12. Emerging Therapies

13. Crohn’s Disease: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Crohn’s Disease

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

View Report: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Request for Detailed TOC: https://www.delveinsight.com/sample-request/crohns-disease-cd-market

Why should you buy this report?

• The report will help in developing business strategies by understanding trends shaping and driving the Crohn’s Disease market

• To understand the future market competition in the Crohn’s Disease market and Insightful review of the key market drivers and barriers

• Organize sales and marketing efforts by identifying the best opportunities for Crohn’s Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan

• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors

• Organize sales and marketing efforts by identifying the best opportunities for Crohn’s Disease market

• To understand the future market competition in the Crohn’s Disease market

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech, and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Related Reports:

· Intrahepatic Cholangiocarcinoma Market

· Barett Esophagus Market

· Aortic Stenosis Market

· Chemotherapy Induced Diarrhea Market

· Immunologic Deficiency Syndrome Market

· Binge Eating Disorder Market

· Acquired Immunodeficiency Syndrome (AIDS) Market

· Bladder pain syndrome Market

· Cardiac Arrythmia Market

· Cardiorenal Syndrome Market

· Carpal Tunnel Syndrome Market

· Central Retinal Venous Occulsion Market

· Foot and Ankle Devices Market